Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

In a propensity score-matched analysis including 754 patients ages 50 and up, use of vedolizumab was associated with a 45.4% risk of treatment failure -- defined as a composite risk of IBD-related ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations ...

Alopecia areata is more prevalent in patients with IBD, especially those on anti-TNF therapy, compared with controls. The study found no significant difference in alopecia improvement between those ...

In a study, veterans who used TNF blockers to treat inflammatory bowel disease had an increased risk for kidney function decline. Anti-tumor necrosis factor (anti-TNF) therapy may increase the risk ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...

Senior man has stomachache Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis. Early ...

Vitamin D significantly affects IBD by influencing severity, inflammation, and patient outcomes. Optimizing vitamin D levels ...

Patients with both inflammatory bowel disease (IBD) and obesity starting on new biologic therapies do not face an increased risk for hospitalization, IBD-related surgery, or serious infection, reveals ...